Wire · opportunities
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Aardvark Therapeutics has cancelled its phase 3 trials after an FDA clinical hold due to cardiac safety concerns. The biotech has reduced its workforce and is currently analysing data to find a regulatory-aligned path forward for its drug candidates, with updates expected later in the year.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Biotech founders developing metabolic disorder treatments must prepare for extended regulatory delays and rethink trial designs to align with new FDA expectations. You need to adjust burn rates and investor communications as pipeline timelines stretch unpredictably.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics